Related Experiment Video
Updated: Sep 17, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Therapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancer
H Parmar1, C D Charlton, R H Phillips
1Charing Cross and Westminster Medical School, London, UK.
Abstract:
Metastatic prostate cancer is well known to respond to hormonal manipulations, but once progression occurs new treatment modalities are required. Specific and systemic antitumour therapy is preferable to local treatments such as radiotherapy in such patients. The finding that somatostatin analogue, BIM 23014, inhibits prostatic tumour growth in animal models is of great interest. We treated 25 poor risk patients with progressive metastatic prostate cancer. Sixteen had also failed to respond to 'total androgen blockade'. Two patients have achieved a partial remission, one of which is maintained at over 30 months, and three had stable disease for over 6 months. Side effects have consisted of mild diarrhoea and abdominal cramp in the first few days of treatment in a minority of the patients. These results are encouraging and further randomized studies are in progress.
Insights
Hormonal therapy resistance in metastatic prostate cancer necessitates new treatments. A somatostatin analogue, BIM 23014, showed encouraging results in patients with advanced prostate cancer, with some achieving remission.
Area of Science:
- Oncology
- Endocrinology
Background:
- Metastatic prostate cancer often becomes resistant to hormonal manipulation.
- New systemic therapies are needed for progressive disease after hormonal blockade.
Purpose of the Study:
- To evaluate the efficacy of the somatostatin analogue BIM 23014 in patients with progressive metastatic prostate cancer.
- To assess the safety and tolerability of BIM 23014 in this patient population.
Main Methods:
- A cohort of 25 patients with progressive metastatic prostate cancer was treated with BIM 23014.
- Sixteen patients had previously failed total androgen blockade.
- Treatment outcomes and side effects were monitored.
Main Results:
- Two patients achieved partial remission, with one sustained for over 30 months.
- Three patients experienced stable disease for over 6 months.
- Side effects were generally mild, including transient diarrhea and abdominal cramps.
Conclusions:
- Somatostatin analogue BIM 23014 demonstrates encouraging activity in patients with advanced, hormone-refractory prostate cancer.
- BIM 23014 appears to be well-tolerated, with manageable side effects.
- Further randomized studies are warranted to confirm these findings.
